Full Time Faculty
The research activities in this laboratory concern the development of novel methods for structural and functional imaging of tissues and cells (based on Optical Coherence Tomography and Optical Elastography techniques).
The research in the Blood Microfluidics laboratory (Prof. Sergey Shevkoplyas) is focused on development and clinical translation of high-throughput microfluidic devices and single-cell analysis tools in the field of blood storage and transfusion medicine. Our goal is to develop technology for eliminating mediators of toxicity from stored blood, and for separating whole blood into components for transfusion in resource-limited settings. A significant additional thrust of our research efforts is the development of low-cost point-of-care diagnostics (e.g., for sickle cell disease).
OMICs-driven research is exploratory in nature, and seeks to interrogate the entire molecular landscape, with the hope of uncovering key pathways or nodes that are aberrant in a disease. Comprehensive profiling using multiple “omics” platforms in our laboratory has yielded novel insights on a wide spectrum of diseases, including autoimmune diseases and cancers. Listed below are key areas of research in MOHANLAB (http://mohanlab.bme.uh.edu/research):
I. Identifying novel biomarkers using proteomics and metabolomics:
Ia. Screening of blood, urine, stools, saliva, CSF and other body fluids for biomarker proteins, using various targeted proteomic
Ib. Engineering higher sensitivity diagnostic platforms for the identification of low-abundance proteins, using electrochemiluminescence
Ic. Identification of metabolite biomarkers using global metabolomics in lupus
Id. Design of point-of-care technologies for home-monitoring of disease biomarkers
Ie. Identification of novel peptoid ligands for biologically important molecules
If. Identification of novel autoantibodies in autoimmune diseases using protein arrays bearing 130, 2500 or 19,000 proteins.
Ig. Biomarker mining from big OMICS datasets using various computational algorithms
II. Defining the role of ALCAM/CD6, BANK1, bradykinins and other molecules in lupus, lupus nephritis, immune activation and inflammation
III. Imaging of end-organ disease in lupus and systemic autoimmunity, using PET-CT, optical imaging and OCT/OCE (details and collaborators are listed at http://mohanlab.bme.uh.edu/ research)
IV: Improved technologies for diagnosing lupus nephritis pathology, including urine biomarkers, machine learning algorithms and near-infrared imaging (details and collaborators are listed at http://mohanlab.bme.uh.edu/research)
V: Emerging Pilot Projects include non-invasive skin-patch monitoring of biomarker molecules, analysis of biomarkers in breath condensates, microfluidic devices for the isolation of specific immune cells, GI-targeted nanoparticle delivery of drugs, characterization of immune cells in 3D splenoids, etc. Details & collaborators are listed at http://mohanlab.bme.uh.edu/research
Research interests of our group include: Development of multi-scale models and simulation of biological pathways and systems; use of simulation-based models of host-pathogen interactions to understand molecular mechanisms of pathogenesis and disease; development of integrated quantitative/empirical platforms to enable predictive modeling and simulation of host-pathogen and multicellular interactions by enabling acquisition of high-resolution kinetic, whole-cell data; the use and application of information theory, coding theory, and signal processing to the analysis of genetic regulatory mechanisms; algorithm development for computational biosensors for detection and classification of polymorphisms, microbial identification and strain classification
My research in image science is devoted to medical imaging, primarily emphasizing the development, assessment, and optimization of imaging systems for detecting cancer. One branch of the work is concerned with devising reliable models for predicting the diagnostic utility of new clinical imaging technology. The second and more expansive branch of work is directed at actually applying these predictive models to design and optimize diagnostic imaging systems. Current areas of interest include gamma-ray imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and x-ray digital tomosynthesis (DT).
The activities in my lab include a variety of basic and translational research in the rapidly growing area of neural engineering and biomedical signal processing. Areas of special interest are: neural decoding for neuroprosthetics; machine learning for neuromarker discovery in cognitive and movement disorders; development of embedded wearable wireless sensors and their integration to intelligent systems for healthcare and assisted living. In particular, we develop novel algorithms and machine learning techniques to explore neural activity recorded in clinical setting. My lab focuses on research that contributes not only to algorithm development but also to the discovery of new methods for diagnosis and therapy that can be applied in clinical practice. In this scheme, our group works closely with clinicians and researchers from diverse fields such as neuroscience, neurosurgery and neurolog
My laboratory has the following research focus: (1) Design and fabrication of novel detection systems for disease diagnostics, this includes protein separation systems, protein chips, nanomaterial-based fluorescent/NIR probes, and surface chemistry for protein binding. The goal is to tackle the existing technological challenges in effective detection of low-abundant proteins and post-translational modified proteins in complex biological samples, especially when these proteins are critical in the pathogenesis of chronic diseases. The development of these novel technologies will aid in high-throughput discovery of early biomarkers, non-invasive biomarkers and therapeutic targets for chronic diseases. In addition, the development of polymer nanofiber based biosensors for biomarker detection has also become of our research interest. (2) Development of versatile and biocompatible nanomaterials for drug delivery to improve bioavailability, effective targeting and controlled release of drugs for chronic diseases. This includes prodrugs and combinatory medicine---the combination of thermotherapy/drug/gene therapy. The goal is to tackle the problems of drug resistance and side-effects commonly seen in today’s medicine for chronic diseases.